Urogen Pharma (NASDAQ:URGN) Receives $33.00 Average PT from Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $33.00.

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 price target on shares of Urogen Pharma in a report on Monday, January 5th. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th.

Insider Buying and Selling

In related news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the sale, the insider directly owned 139,025 shares of the company’s stock, valued at $3,475,625. The trade was a 6.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. CWM LLC increased its holdings in shares of Urogen Pharma by 18.0% in the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock valued at $85,000 after acquiring an additional 650 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Urogen Pharma by 9.4% during the second quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock worth $127,000 after purchasing an additional 797 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after purchasing an additional 1,653 shares during the period. Main Street Financial Solutions LLC increased its stake in Urogen Pharma by 8.2% during the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock valued at $356,000 after purchasing an additional 1,968 shares during the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the period. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Price Performance

NASDAQ:URGN opened at $18.80 on Friday. The firm has a 50-day moving average of $23.58 and a two-hundred day moving average of $20.00. The stock has a market cap of $880.03 million, a P/E ratio of -5.43 and a beta of 1.29. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $30.00.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.03. The business had revenue of $27.48 million for the quarter, compared to analysts’ expectations of $34.09 million. As a group, equities analysts expect that Urogen Pharma will post -3.12 earnings per share for the current year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.